BOSTON, Feb. 9, 2018 /PRNewswire/ -- Kyros Law
Offices is alerting investors of Akorn Pharmaceuticals (NASDAQ:
AKRX) that it is filing legal claims on behalf of investors against
the company for possible securities fraud violations..
Akorn Pharmaceuticals (NASDAQ: AKRX) investors that purchased
stock BETWEEN MAY 6, 2014 AND
APRIL 24, 2015 are urged to
contact our law firm immediately to protect their rights. Visit
our AKRX Shareholder Lawsuit Settlement webpage or
call 1-800-934-2921 to speak to someone about your case. Your legal
rights will be affected whether you act or do not act. If you do
not act, you may permanently forfeit your right to recover on this
claim.
Akorn Pharmaceuticals (NASDAQ: AKRX) will pay $24 million to settle a class action lawsuit
accusing the company of inflating revenue figures and using faulty
accounting practices after a federal judge granted preliminary
approval for a deal between the two parties in United States District Court for the Northern
District of Illinois, Eastern
Division.
Kyros Law Offices urges Akorn Pharmaceuticals (NASDAQ: AKRX)
investors to contact our law firm immediately to protect their
rights. Visit Akorn Pharmaceuticals (NASDAQ: AKRX) Lawsuit
Settlement or call 1-800-934-2921 to find out if you have a
case.
Due to the terms of the proposed settlement, your legal
rights will be affected whether you act or do not act. If you do
not act, you may permanently forfeit your right to recover on this
claim.
Kyros Law specializes in a
wide range of complex litigation, mass torts, and corporate
governance matters, including the representation of whistleblowers,
shareholders and consumers in securities fraud, false claims act
and class actions. Our lawyers have been responsible for recovering
hundreds of millions of dollars for our clients throughout
the United States, Africa, Asia
and Europe. Visit our
website to learn more about our firm.
View original
content:http://www.prnewswire.com/news-releases/akrx-investor-alert-kyros-law-is-filing-compensation-claims-on-behalf-of-akorn-pharmaceuticals-nasdaq-akrx-investors-300596403.html
SOURCE Kyros Law